Chris Markoch

Chris Markoch

InvestorPlace Contributor

Chris Markoch is a freelance financial writer who brings over 25 years in sales and marketing to help find the story behind the stock. Chris starts by asking the question, “So what?” and then uses fundamental and (some) technical analysis to add depth to that insight.

Stepping back from the “what” allows Chris to bring perspective that helps investors make wise decisions based on their risk tolerance and investing timeline.

Markoch would describe his writing as being for investors more than traders. He looks at equities through a long-term lens and that is reflected in his writing.

In addition to his articles on InvestorPlace, you can also find Chris’ writing on MarketBeat.com where he has collaborated on the e-book “5 Investing Trends That Will Define the Market in 2022.” You can find Chris on LinkedIn and on Twitter.

Recent Articles

JFrog Held An IPO, But You Don’t Have to Buy It’s Stock

By Chris Markoch, InvestorPlace Contributor

FROG stock nearly doubled post-IPO, but it's falling. And this is your timely reminder that IPOs don't always benefit early investors.

6 Red-Hot Upcoming IPOs To Close Out a Record Year

By Chris Markoch, InvestorPlace Contributor

After a slow start due to the pandemic, initial public offering activity is picking up. Here are six upcoming IPOs that may launch this quarter.

Don’t Get Silly When Looking at General Electric

By Chris Markoch, InvestorPlace Contributor

GE stock has been making large moves, mostly based on hopes for more economic stimulus. But any news, good or bad, is baked into the stock.

What More Does Nokia Have to Do?

By Chris Markoch, InvestorPlace Contributor

Nokia stock dropped 18% in September despite a new CEO and a string of 5G wins. Is the stock just following the market, or is there more to the story?

Inovio Pharmaceuticals Does Not Need Any More Misfortune

By Chris Markoch, InvestorPlace Contributor

INO stock is plummeting after the FDA put a hold on its INO-4800 vaccine candidate. But by the time Inovio resumes the trial, will a vaccine be needed?

Time Is Not the Friend of Luckin Stock

By Chris Markoch, InvestorPlace Contributor

Luckin stock continues to stabilize as the company looks to regain investors' trust. But that may not be the company's biggest problem.

3 Things to Watch from Domino’s Pizza Before Earnings

By Chris Markoch, InvestorPlace Contributor

DPZ stock fell in the six weeks after its stellar earnings report. But analysts believe that the strong fundamentals from the prior report are still in place.

The Real Value in Novavax Goes Beyond the Coronavirus

By Chris Markoch, InvestorPlace Contributor

NVAX stock is up over 2,000% on hopes it will deliver a vaccine for the novel coronavirus. However, the real value comes from its influenza vaccine.

Sorrento Therapeutics Is Simply Running Out of Time

By Chris Markoch, InvestorPlace Contributor

SRNE stock is up over 200% because the company is taking several bites at the Covid-19 apple. However time is not on the company's side.

5 Stocks to Play the Upcoming Election

By Chris Markoch, InvestorPlace Contributor

Investors trying to pick election stocks should look at names that are likely to perform well no matter who occupies 1600 Pennsylvania Avenue.

Load More